Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA

Launched by UNIVERSITY HOSPITAL, CAEN · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to monitor patients with low-grade gliomas, which are a type of brain tumor. Researchers are looking at tiny molecules called microRNAs that can be found in the blood. These microRNAs may help detect when the tumor is coming back after treatment, even before it shows up on an MRI scan. The hope is that by using these markers, doctors can identify recurrences earlier and start treatment sooner, which could be beneficial for patients.

To participate in this trial, patients need to be adults who have been diagnosed with a grade 2 or 3 diffuse glioma and have had surgery at the Caen University Hospital. They must also be receiving care at this hospital and be part of a social security system. Patients will be monitored over time, and their blood samples will be tested for these microRNAs. This study is important because it aims to improve how we track glioma patients and potentially enhance their treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major patient
• • Suffered from a grade 2-3 diffuse glioma
• • Surgery in the neurosurgery department of Caen University Hospital
• • Patient affiliated to a social security scheme
• • Patient followed at Caen University Hospital
• • No opposition from the patient
• Exclusion Criteria:
• • Patients who have undergone biopsy (lack of material for the study, limited value of monitoring for these patients without surgical excision)
• • Patients with grade 1 circumscribed glioma
• • Patients with grade 4 glioma
• • Other non-glial histologies, glioneuronal histology
• • Minor patients
• • Patient not affiliated to a social security scheme
• • Major under guardianship or protected